
    
      This is a phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel dose
      cohort study to evaluate the efficacy and safety of PB-119 to patients with T2DM not
      well-controlled by metformin monotherapy. Patients will be assessed for eligibility over a 2
      week screening period prior to a 4-week run-in period,a 24-week double-blind treatment period
      and a 28-week open-label treatment period. The eligible patients will be randomized to PB-119
      or placebo cohort at a 1:1 ratio for the first 24-week. Patients in PB-119 group will
      subsequently be given active drug and patients in placebo group will take placebo, all
      patients in two groups will remain metformin background therapy. In the 28-week open-label
      period, all patients will be administered active drugs. After that, there will be a 4-week
      follow-up period; All randomized patients will be taken blood samples for the pharmacokinetic
      (PK) analysis.
    
  